Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niuliva for prevention of hepatitis B recurrence after orthotopic liver transplantation
2010-020931-37Phase 3Completed
- Sponsor
- Grifols
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nivolumab in hepatitis B (HBV), sponsored by Grifols. Primary endpoints: Percentage of subjects with HBV-liver disease recurrence during the first 6 months after transplantation and Percentage of subjects with protective pre-infusion HBsAb trough levels. Started Sep 2010; status: completed.
02
Drugs
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2010-020931-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020931-37.